Phielix, E <br/><br/>
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Oct 2013 
 - 915-22 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12112  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adiponectin--blood<br/>Blood Glucose--metabolism<br/>Body Mass Index<br/>C-Reactive Protein--metabolism<br/>Cyclohexanes--therapeutic use<br/>Diabetes Mellitus, Type 2--blood<br/>Double-Blind Method<br/>Female<br/>Glycated Hemoglobin--metabolism<br/>Hepatocytes--metabolism<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Insulin--therapeutic use<br/>Insulin Resistance<br/>Lipid Metabolism--drug effects<br/>Lipolysis--drug effects<br/>Male<br/>Middle Aged<br/>Nateglinide<br/>Phenylalanine--analogs & derivatives<br/>Pioglitazone<br/>Sulfonylurea Compounds--therapeutic use<br/>Thiazolidinediones--therapeutic use<br/>Treatment Outcome